The following Overview, *** BENZOYL PEROXIDE ***, is relevant for this HSDB record chemical.

   o   This overview assumes that basic life support measures
       have been instituted.

  0.2.1 SUMMARY OF EXPOSURE
   0.2.1.1 ACUTE EXPOSURE
     A)  WITH POISONING/EXPOSURE
      1)  Benzoyl peroxide may be irritating to the eyes, skin,
          and mucous membranes. Signs and symptoms of exposure
          may include decreased pulse and temperature, dyspnea
          and wheezing, abdominal pain, and stupor.
      2)  Conjunctival inflammation and superficial corneal
          opacity have been noted when benzoyl peroxide was
          applied to the eyes of experimental animals. Allergic
          dermatitis may occur.
  0.2.4 HEENT
   0.2.4.1 ACUTE EXPOSURE
     A)  WITH POISONING/EXPOSURE
      1)  Conjunctivitis may be noted from ocular exposure.
  0.2.14 DERMATOLOGIC
   0.2.14.1 ACUTE EXPOSURE
     A)  WITH THERAPEUTIC USE
      1)  Skin contact causes primary and sensitization
          dermatitis. Moderate erythema and edema have followed
          topical exposure to 10% solutions.
  0.2.20 REPRODUCTIVE HAZARDS
    A)  Benzoyl peroxide is classified as FDA pregnancy category
        C. There are no adequate and well-controlled studies of
        benzoyl peroxide use in pregnant women. It is not known
        if benzoyl peroxide is excreted in the breast milk.
  0.2.21 CARCINOGENICITY  致癌问题
   0.2.21.1 IARC CATEGORY
     A)  IARC Carcinogenicity Ratings for CAS94-36-0 (IARC,
         2004):
      1)  IARC Classification
       a)  Listed as: Benzoyl peroxide
       b)  Carcinogen Rating: 3
        1)  The agent (mixture or exposure circumstance) is not
            classifiable as to its carcinogenicity to humans.
            This category is used most commonly for agents,
            mixtures and exposure circumstances for which the
            evidence of carcinogenicity is inadequate in humans
            and inadequate or limited in experimental animals.
            Exceptionally, agents (mixtures) for which the
            evidence of carcinogenicity is inadequate in humans
            but sufficient in experimental animals may be placed
            in this category when there is strong evidence that
            the mechanism of carcinogenicity in experimental
            animals does not operate in humans. Agents, mixtures
            and exposure circumstances that do not fall into any
            other group are also placed in this category.

   A)  The L929 mouse fibroblast cell line may exhibit similar
       benzoyl peroxide exposure characteristics as human eye
       fibroblasts. Thus the L929 cell line may have application
       for testing the cytotoxic vapor effects from benzoyl
       peroxide containing dental products.

  0.4.2 ORAL EXPOSURE
    A)  DILUTION: Immediately dilute with 4 to 8 ounces (120 to
        240 mL) of water or milk (not to exceed 4 ounces/120 mL
        in a child).
  0.4.3 INHALATION EXPOSURE
    A)  INHALATION: Move patient to fresh air. Monitor for
        respiratory distress. If cough or difficulty breathing
        develops, evaluate for respiratory tract irritation,
        bronchitis, or pneumonitis. Administer oxygen and assist
        ventilation as required. Treat bronchospasm with inhaled
        beta2 agonist and oral or parenteral corticosteroids.
  0.4.4 EYE EXPOSURE
    A)  DECONTAMINATION: Irrigate exposed eyes with copious
        amounts of room temperature water for at least 15
        minutes. If irritation, pain, swelling, lacrimation, or
        photophobia persist, the patient should be seen in a
        health care facility.
  0.4.5 DERMAL EXPOSURE
    A)  OVERVIEW
     1)  DECONTAMINATION: Remove contaminated clothing and wash
         exposed area thoroughly with soap and water. A
         physician may need to examine the area if irritation or
         pain persists.
     2)  Vitamin E may be of use in therapy.

   A)  Human exposure to 12.2 mg/m(3) produces nose and throat
       irritation.